Fig. 3.

Improvements in ASDAS and BASDAI total score. Proportions of patients with improvement in ASDAS of a ≥ 1.1 points and b ≥ 2.0 points, and c ≥ 50% in BASDAI total score at each study visit. Vertical dotted line indicates week 16, after which all patients received open-label tofacitinib until week 48. The 50th percentile line is to facilitate interpretation of the results. ASDAS, Ankylosing Spondylitis Disease Activity Score C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BID, twice daily